280 related articles for article (PubMed ID: 12634234)
21. Effect of the B cell superantigen protein A from S. aureus on the early lupus disease of (NZBxNZW) F1 mice.
Viau M; Zouali M
Mol Immunol; 2005 May; 42(7):849-55. PubMed ID: 15829273
[TBL] [Abstract][Full Text] [Related]
22. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus.
Amoura Z; Koutouzov S; Chabre H; Cacoub P; Amoura I; Musset L; Bach JF; Piette JC
Arthritis Rheum; 2000 Jan; 43(1):76-84. PubMed ID: 10643702
[TBL] [Abstract][Full Text] [Related]
23. Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis.
Ozmen L; Roman D; Fountoulakis M; Schmid G; Ryffel B; Garotta G
Eur J Immunol; 1995 Jan; 25(1):6-12. PubMed ID: 7843255
[TBL] [Abstract][Full Text] [Related]
24. T cell cytokine imbalance towards production of IFN-gamma and IL-10 in NZB/W F1 lupus-prone mice is associated with autoantibody levels and nephritis.
Enghard P; Langnickel D; Riemekasten G
Scand J Rheumatol; 2006; 35(3):209-16. PubMed ID: 16766368
[TBL] [Abstract][Full Text] [Related]
25. Preventive effect of a novel antifolate, MX-68, in murine systemic lupus erythematosus (SLE).
Mihara M; Takagi N; Urakawa K; Moriya Y; Takeda Y
Int J Immunopharmacol; 1997 Feb; 19(2):67-74. PubMed ID: 9278176
[TBL] [Abstract][Full Text] [Related]
26. Estrogen receptor alpha promotes lupus in (NZB×NZW)F1 mice in a B cell intrinsic manner.
Tabor DE; Gould KA
Clin Immunol; 2017 Jan; 174():41-52. PubMed ID: 27989899
[TBL] [Abstract][Full Text] [Related]
27. Immunomodulatory effects of H.P. Acthar Gel on B cell development in the NZB/W F1 mouse model of systemic lupus erythematosus.
Decker DA; Grant C; Oh L; Becker PM; Young D; Jordan S
Lupus; 2014 Jul; 23(8):802-12. PubMed ID: 24759631
[TBL] [Abstract][Full Text] [Related]
28. Tamoxifen alleviates disease severity and decreases double negative T cells in autoimmune MRL-lpr/lpr mice.
Wu WM; Suen JL; Lin BF; Chiang BL
Immunology; 2000 May; 100(1):110-8. PubMed ID: 10809966
[TBL] [Abstract][Full Text] [Related]
29. CXCR3 promotes the production of IgG1 autoantibodies but is not essential for the development of lupus nephritis in NZB/NZW mice.
Moser K; Kalies K; Szyska M; Humrich JY; Amann K; Manz RA
Arthritis Rheum; 2012 Apr; 64(4):1237-46. PubMed ID: 22006377
[TBL] [Abstract][Full Text] [Related]
30. MHC class I expression regulates susceptibility to spontaneous autoimmune disease in (NZBxNZW)F1 mice.
Mozes E; Lovchik J; Zinger H; Singer DS
Lupus; 2005; 14(4):308-14. PubMed ID: 15864917
[TBL] [Abstract][Full Text] [Related]
31. Effect of murine recombinant IL-2 on the course of lupus-like disease in (NZBxNZW) F1 female mice.
Ravel G; Christ M; Ruat C; Burnett R; Descotes J
Immunopharmacol Immunotoxicol; 2002 Aug; 24(3):409-21. PubMed ID: 12375737
[TBL] [Abstract][Full Text] [Related]
32. Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease.
Youd M; Blickarz C; Woodworth L; Touzjian T; Edling A; Tedstone J; Ruzek M; Tubo R; Kaplan J; Lodie T
Clin Exp Immunol; 2010 Jul; 161(1):176-86. PubMed ID: 20456409
[TBL] [Abstract][Full Text] [Related]
33. Prevention of lupus nephritis development in NZB/NZW mice by selective blockade of CD28.
Laurent L; Le Fur A; Bloas RL; Néel M; Mary C; Moreau A; Poirier N; Vanhove B; Fakhouri F
Eur J Immunol; 2017 Aug; 47(8):1368-1376. PubMed ID: 28631301
[TBL] [Abstract][Full Text] [Related]
34. A peptide derived from a polyreactive monoclonal anti-DNA natural antibody can modulate lupus development in (NZBxNZW)F1 mice.
Jouanne C; Avrameas S; Payelle-Brogard B
Immunology; 1999 Mar; 96(3):333-9. PubMed ID: 10233713
[TBL] [Abstract][Full Text] [Related]
35. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice.
Foell J; Strahotin S; O'Neil SP; McCausland MM; Suwyn C; Haber M; Chander PN; Bapat AS; Yan XJ; Chiorazzi N; Hoffmann MK; Mittler RS
J Clin Invest; 2003 May; 111(10):1505-18. PubMed ID: 12750400
[TBL] [Abstract][Full Text] [Related]
36. Cross-reactivity of antiidiotypic antibodies with DNA in systemic lupus erythematosus.
Eivazova ER; McDonnell JM; Sutton BJ; Staines NA
Arthritis Rheum; 2000 Feb; 43(2):429-39. PubMed ID: 10693885
[TBL] [Abstract][Full Text] [Related]
37. Tuftsin-phosphorylcholine (TPC) equally effective to methylprednisolone in ameliorating lupus nephritis in a mice model.
Shemer A; Kivity S; Shovman O; Bashi T; Perry O; Watad A; Ben-Ami Shor D; Volkov A; Barshack I; Bragazzi NL; Krule A; Fridkin M; Amital H; Blank M; Shoenfeld Y
Clin Exp Immunol; 2018 Aug; 193(2):160-166. PubMed ID: 29698559
[TBL] [Abstract][Full Text] [Related]
38. Circulating levels of chromatin fragments are inversely correlated with anti-dsDNA antibody levels in human and murine systemic lupus erythematosus.
Jørgensen MH; Rekvig OP; Jacobsen RS; Jacobsen S; Fenton KA
Immunol Lett; 2011 Aug; 138(2):179-86. PubMed ID: 21530588
[TBL] [Abstract][Full Text] [Related]
39. The Systemic Activation of Programmed Death 1-PD-L1 Axis Protects Systemic Lupus Erythematosus Model from Nephritis.
Liao W; Zheng H; Wu S; Zhang Y; Wang W; Zhang Z; Zhou C; Wu H; Min J
Am J Nephrol; 2017; 46(5):371-379. PubMed ID: 29069649
[TBL] [Abstract][Full Text] [Related]
40. X-linked immunodeficient mice spontaneously produce lupus-related anti-RNA helicase A autoantibodies, but are resistant to pristane-induced lupus.
Satoh M; Mizutani A; Behney KM; Kuroda Y; Akaogi J; Yoshida H; Nacionales DC; Hirakata M; Ono N; Reeves WH
Int Immunol; 2003 Sep; 15(9):1117-24. PubMed ID: 12917264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
